COVID-19: the new challenge for rheumatologists
https://doi.org/10.14412/1996-7012-2020-2-110-116
Abstract
Currently, the infection caused by the new coronavirus COVID-19 is considered by the global community as an emergency of international concern. Rheumatologists are particularly concerned about this problem, since patients with immune-mediated inflammatory rheumatic diseases (IMIRDs) are at higher risk for infectious diseases and receive immunosuppressive treatment. The use of disease-modifying antirheumatic drugs and biological agents increases the incidence of serious infections, but insufficient/no monitoring of IMIRD activity is an even greater risk factor for infectious complications. In addition, the role of vaccination mainly against influenza and pneumococcal infection is substantially increasing in modern conditions, since the risk of death from respiratory tract infections is quite high in patients with IMIRDs, which is very important in the context of the current COVID-19 pandemic.
The paper presents an update on the incidence of viral infections in patients with IMIRDs and also discusses whether antirheumatic drugs can be used to treat COVID-19.
About the Authors
B. S. Belov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
A. E. Karateev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22; 395(10224):565-74. doi: 10.1016/S01406736(20)30251-8
2. Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020 Mar;63(3):457-60. doi: 10.1007/s11427-020-1637-5
3. Zhao Y, Zhao Z, Wang Y, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Biorxiv. 2020;2020(1):26.919985. doi: 10.1101/2020.01.26.919985
4. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. doi: 10.1016/S0140-6736(20)30628-0.
5. Seguin A, Galicier L, Boutboul D, et al. Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis. Chest. 2016 May;149(5):1294-301. doi: 10.1016/j.chest.2015.11.004. Epub 2016 Jan 13.
6. Liu T, Zhang J, Yang Y, et al. The potential role of interleukin 6 in monitoring severe case of coronavirus disease. medRxiv; 2020. doi: 10.1101/2020/03/01/20029769
7. Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020 Mar 17. doi: 10.1002/jmv.25770. [Epub ahead of print]
8. Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011 May;70(5): 785-91. doi: 10.1136/ard.2010.128637. Epub 2011 Feb 2.
9. Accortt NA, Lesperance T, Liu M, et al. Impact of sustained remission on the risk of serious infection in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2018 May;70(5):679-84. doi: 10.1002/acr.23426. Epub 2018 Mar 11.
10. Polyanskaya MV. Pneumonia in patients with rheumatic diseases: incidence, clinical presentation, risk factors. Автореф. дисс. ... канд. мед. sci. Moscow; 2009. 24 p.
11. Zhang J, Zeng H, Gu J, et al. Progress and Prospects on Vaccine Development against SARS-CoV-2. Vaccines (Basel). 2020; 8(2):E153. doi:10.3390/vaccines8020153
12. EULAR Guidance for patients COVID-19 outbreak. Available from: https://www.eular.org/eular_guidance_for_patients_covid19_outbreak.cfm
13. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14.
14. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
15. Karateev AE, Nasonov EL, Lila AM. Do NSAIDs cause specific complications in COVID-19 coronavirus infection? Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2020. (In Russ.). Available from: https://rheumatolog.su/media/media/2020/04/03/npr_2020_2.pdf
16. Kim SY, Chang YJ, Cho HM, et al. Nonsteroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev. 2015 Sep 21;(9):CD006362. doi: 10.1002/14651858.CD006362.pub4
17. Lanas A, McCarthy D, Voelker M, et al. Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds – gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. Drugs R D. 2011 Sep 1; 11(3):277-88. doi: 10.2165/11593880000000000-00000
18. Lee BH, Inui D, Suh GY, et al. Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: multi-centered prospective observational study. Crit Care. 2012 Feb 28;16(1):R33. doi: 10.1186/cc11211
19. Voiriot G, Philippot Q, Elabbadi A, et al. Risks Related to the Use of Non-Steroidal Anti-Inflammatory Drugs in CommunityAcquired Pneumonia in Adult and Pediatric Patients. J Clin Med. 2019 Jun 3;8(6). pii: E786. doi: 10.3390/jcm8060786
20. Drewry A, Ablordeppey E, Murray E, et al. Antipyretic Therapy in Critically Ill Septic Patients: A Systematic Review and Meta-Analysis. Crit Care Med. 2017 May; 45(5):806-13. Published online 2017 Apr 14. doi: 10.1097/CCM.0000000000002285
21. Schenfeld J, Iles J, Trivedi M, Accortt NA. Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis. Rheumatol Int. 2017 Jul;37(7):1075-82. doi: 10.1007/s00296-017-3679-4. Epub 2017 Mar 2.
22. Ni YN, Chen G, Sun J, et al. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and metaanalysis. Crit Care. 2019 Mar 27; 23(1):99. doi: 10.1186/s13054-019-2395-8
23. World Health Organization. Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019nCoV) Infection is Suspected: Interim Guidance. 2020.
24. Nasonov EL, Lila AM, Mazurov VI, et al. Coronavirus disease 2019 (COVID-19) and immuno-inflammatory (autoimmune) rheumatic diseases. Draft recommendations of the all-Russian public organization «Association of rheumatologists of Russia».. Available from: https://rheumatolog.ru/sites/default/files/klinicheskie_rekomendacii_koronavirusnaya_bolezni_i_rz_poslednyaya_versiya_0.pdf
25. Dirven L, Huizinga TW, Allaart CF. Risk factors for reported influenza and influenzalike symptoms in patients with rheumatoid arthritis. Scand J Rheumatol. 2012;41(5): 359-65. doi: 10.3109/03009742.2012.670729
26. Bello SL, Serafino L, Bonali C, et al. Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents. Reumatismo. 2012;64(5):299-306. doi: 10.4081/reumatismo.2012.299
27. Monti S, Balduzzi S, Delvino P, et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020 May;79(5):667-8. doi: 10.1136/annrheumdis-2020-217424
28. Keyaerts E, Vijgen L, Maes P, et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004 Oct 8; 323(1):264-8.
29. Paton NI, Lee L, Xu Y, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2011 Sep;11(9):677-83. doi: 10.1016/S1473-3099(11)70065-2. Epub 2011 May 5.
30. Roques P, Thiberville SD, DupuisMaguiraga L, et al. Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection. Viruses. 2018 May 17; 10(5). pii: E268. doi: 10.3390/v10050268
31. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22;2:69.
32. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 Mar 12:105938. doi: 10.1016/j.ijantimicag.2020.105938. [Epub ahead of print].
33. Savarino A, Trani LD, Donatelli I, et al. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006 Feb;6(2): 67-9.
34. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID19: results of a randomized clinical trial. medRxiv. 2020. doi: 10.1101/2020.03.22.20040758
35. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-3. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.
36. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. pii: ciaa237. doi:10.1093/cid/ciaa237. [Epub ahead of print]
37. Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;S08839441(20)30390-7. doi: 10.1016/j.jcrc.2020.03.005
38. Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020; 369:m1432. doi:10.1136/bmj.m1432
39. Shah S, Das S, Jain A, et al. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19) [published online ahead of print, 2020 Apr 13]. Int J Rheum Dis. 2020 Apr 13. doi: 10.1111/1756-185X.13842. [Epub ahead of print]
40. Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 Receptor Blockade Is Associated with Reduced Mortality in Sepsis Patients with Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit Care Med. 2016;44(2): 275-281. doi: 10.1097/CCM.0000000000001402
41. Xu X, Han M, Li T, et al. Effective treatment os severe COVID-19 patients with tocilizumab. ChinaXiv: 20200300026. 2020.
42. Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19 (TACOS). Available from: https://clinicaltrials.gov/ct2/show/NCT04306705
43. Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) (TOCIVID-19). Available from: https://clinicaltrials.gov/ct2/show/NCT04317092
44. Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis (COVIDOSE). Available from: https://clinicaltrials.gov/ct2/show/NCT04331795
45. Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19. Available from: https://clinicaltrials.gov/ct2/show/NCT04315298
46. Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 5 (08.04.2020). Available from: https://www.rosminzdrav.ru/ministry/med_covid19
47. «R-Pharm» launched clinical trials of drugs for coronavirus infection. Available from: https://vademec.ru/news/2020/04/06/r-farmnachal-klinicheskie-ispytaniya-dvukh-svoikhpreparatov-ot-koronavirusnoy-infektsii/
48. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-80.e8. doi: 10.1016/j.cell.2020.02.052
49. Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224): 565-74. doi: 10.1016/S0140-6736(20)30251-8
50. Bekerman E, Neveu G, Shulla A, et al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest. 2017; 127(4):1338-52. doi: 10.1172/JCI89857
51. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019nCoV acute respiratory disease. Lancet. 2020;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4
52. Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33(1):15-32. doi: 10.1007/s40259-019-00333-w
53. Kelesidis T, Mastoris I, Metsini A, Tsiodras S. How to approach and treat viral infections in ICU patients. BMC Infect Dis. 2014 Nov 28;14:321. doi: 10.1186/14712334-14-321
54. Favalli EG, Biggioggero M, Maioli G, Caporali R. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. 2020 Apr 3. pii: S1473-3099(20)30262-0. doi: 10.1016/S1473-3099(20)30262-0. [Epub ahead of print]
Review
For citations:
Belov BS, Karateev AE. COVID-19: the new challenge for rheumatologists. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2020;14(2):110-116. https://doi.org/10.14412/1996-7012-2020-2-110-116
Views:
21168
Email this article 